Walder Wyss Guides Altamira Therapeutics in Strategic Venture

Nasdaq-listed Altamira Therapeutics has successfully navigated a strategic repositioning with the assistance of legal counsel from Walder Wyss. The innovative move involved the sale of a 51% stake in its subsidiary, Altamira Medica, to a Swiss private equity investor. This strategic maneuver aligns with Altamira’s focus on advancing its RNA delivery technology.

In a transaction structured for impact, Altamira received a substantial cash consideration for the 51% stake and retained the prospect of earning 25% of Altamira Medica’s future licensing income. The deal extended beyond borders, including the sale of Auris Medical in Australia and a proportional cash contribution to Altamira Medica’s equity by its two shareholders.

Led by the dynamic duo of partner Alex Nikitine (pictured left) and counsel Iliana Djagova (pictured right, both corporate/M&A), the Walder Wyss team included Fabienne Limacher (partner, tax), Erik Lanz (associate, corporate/M&A), Natascha Rizzi (associate, tax) and Arbër Hyseni (trainee lawyer, corporate/M&A).